InSite Vision Inc. (fka INSV)

[stocktrademan]

InSite Vision, Inc. [$INSV] due diligence

bullish
excellent long term bullish macd bullish divergence




$INSV

DD Notes ~ http://www.ddnotesmaker.com/INSV

##### recent news/filings ~ source: finance.yahoo.com

Tue, 08 Jul 2014 12:49:13 GMT ~ InSite Vision Plans to Submit New Drug Application to FDA for DexaSite™ for the Treatment of Blepharitis in Adults
[at noodls] - DexaSite NDA Submission Planned for 2015; AzaSite Plus™ Data and Endpoint Discussions with FDA Continue European post-Phase 3/pre-MAA DexaSite and AzaSite Plus Blepharitis Discussions Scheduled for Q3 ...
read full: http://www.noodls.com/view/448A1A5464E62D71A8153AF5D433A244FE358F89
*********************************************************

Tue, 08 Jul 2014 12:30:00 GMT ~ InSite Vision Plans to Submit New Drug Application to FDA for DexaSite™ for the Treatment of Blepharitis in Adults
[Business Wire] - Following a June 16, 2014 meeting with the U.S. Food and Drug Administration , InSite Vision Incorporated today announced that it intends to submit a New Drug Application for DexaSite™ as a treatment for blepharitis in adults during 2015, following completion of remaining chemistry and manufacturing work.
read full: http://finance.yahoo.com/news/insite-vision-plans-submit-drug-123000605.html
*********************************************************

Fri, 13 Jun 2014 20:30:20 GMT ~ INSITE VISION INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitiv
read full: http://biz.yahoo.com/e/140613/insv8-k.html
*********************************************************

Thu, 12 Jun 2014 12:32:28 GMT ~ InSite Vision reports agreement with noteholders to extinguish debt
read full: http://www.theflyonthewall.com/permalinks/entry.php/INSVid2024158/INSV-InSite-Vision-reports-agreement-with-noteholders-to-extinguish-debt
*********************************************************

Thu, 12 Jun 2014 12:30:00 GMT ~ InSite Vision Announces Agreement With Noteholders to Extinguish Debt in Exchange for One-Time Payment
[Business Wire] - InSite Vision Incorporated today announced that the Azithromycin PhaRMA Secured 16% Notes due 2019, issued by its wholly owned subsidiary, have been cancelled for a s
read full: http://finance.yahoo.com/news/insite-vision-announces-agreement-noteholders-123000341.html
*********************************************************

##### chart ~ source: stockcharts.com



##### chart ~ source: eoddata.com



##### company info ~ source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/INSV/company-info
Ticker: $INSV
OTC Market Place: OTCQB
CIK code: 0000802724
Company name: InSite Vision, Inc.
Company website: http://www.insitevision.com
Incorporated In: DE, USA

##### extra dd links

Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000802724&owner=exclude&count=40
Latest filings: http://www.otcmarkets.com/stock/INSV/filings
Latest financials: http://www.otcmarkets.com/stock/INSV/financials
Latest news: http://www.otcmarkets.com/stock/INSV/news - http://finance.yahoo.com/q/h?s=INSV+Headlines

Major holdings: http://data.cnbc.com/quotes/INSV/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=INSV+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/INSV.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=INSV

RegSho: http://www.regsho.com/tools/symbol_stats.php?sym=INSV&search=search

DTCC: http://search2.dtcc.com/?q=InSite+Vision%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&q=InSite+Vision%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results?term=InSite+Vision%2C+Inc.&x=0&y=0
WHOIS: http://whois.domaintools.com/http://www.insitevision.com
Alexa: http://www.alexa.com/siteinfo/http://www.insitevision.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.insitevision.com

Short Sales: http://www.otcmarkets.com/stock/INSV/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/INSV/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/INSV/research
Historical Prices: http://finance.yahoo.com/q/hp?s=INSV+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=INSV+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=INSV+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=INSV+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=INSV+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=INSV+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=INSV
Balance Sheet: http://finance.yahoo.com/q/bs?s=INSV
Cash Flow: http://finance.yahoo.com/q/cf?s=INSV+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/INSV
Bloomberg: http://www.bloomberg.com/quote/INSV:US
Morningstar: http://quotes.morningstar.com/stock/s?t=INSV
Bussinessweek: http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=INSV
Barchart: http://www.barchart.com/quotes/stocks/INSV
OTC Short Report: http://otcshortreport.com/index.php?index=INSV
Investopedia: http://www.investopedia.com/markets/stocks/INSV/?wa=0

http://www.pennystocktweets.com/stocks/profile/INSV

##### last known share structure ~ source: otcmarkets.com

Market Value: $40,508,967 a/o Jul 11, 2014
Shares Outstanding: 131,951,033 a/o Aug 12, 2013
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01

##### business description ~ source: otcmarkets.com

InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. The Company's lead product is AzaSite*, which targets infections of the eye. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite, InSite Vision's patented drug-delivery vehicle, which offers the benefit of a low-dosing regimen, attractive to both the eye-care patient and physician.AzaSite was launched in the United States in August 2007 by Inspire Pharmaceuticals, InSite Vision's commercial partner for the U.S. and Canada. The company's product development portfolio also includes ISV-502 (AzaSite Plus), which is currently in Phase 3 pivotal trials for the treatment of eyelid infection and inflammation, and additional product candidates leveraging the company's core DuraSite technology platform. InSite has recently advanced two new product candidates for the treatment of eye pain and inflammation into preclinical testing.InSite Vision's strategy includes maximizing AzaSite sales in the U.S. and abroad through close collaboration with marketing partners, seeking development partners for its DuraSite-enabled early-stage product candidates, and applying the company's expertise in ophthalmology to identify, in-license, or acquire promising new product candidates or technologies.Less >>

DD Notes ~ http://www.ddnotesmaker.com/INSV
a11k